Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dragana Bugarski-Kirola

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 5, 2021
Comorbidities and behavioral issuesDragana Bugarski-Kirola, Ronald N Marcus
Schizophrenia Research|August 1, 2013
Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysisJonathan Rabinowitz, Carmen Galani Berardo, Dragana Bugarski-Kirola, et al.
Schizophrenia Bulletin|April 4, 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative SymptomsDragana Bugarski-Kirola, I-Yuan Liu, Celso Arango, et al.
Schizophrenia Bulletin Open|August 15, 2024
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic TreatmentDragana Bugarski-Kirola, Istvan Bitter, I-Yuan Liu, et al.
Frontiers in Psychiatry|September 23, 2022
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophreniaDragana Bugarski-Kirola, Rene Nunez, Ramzey Odetalla, et al.
Patient Preference and Adherence|January 24, 2024
Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE StudiesDragana Bugarski-Kirola, Brandon Abbs, Ramzey Odetalla, et al.
Journal of Clinical Psychopharmacology|October 3, 2022
Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE StudyMona Darwish, Dragana Bugarski-Kirola, Julie Passarell, et al.
Schizophrenia Research|February 10, 2012
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE dataJonathan Rabinowitz, Stephen Z Levine, George Garibaldi, et al.
Journal of Clinical Pharmacology|July 20, 2023
Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of PimavanserinMona Darwish, Dragana Bugarski-Kirola, David Jaworowicz, et al.
The Lancet. Psychiatry|December 3, 2021
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and EuropeDragana Bugarski-Kirola, Celso Arango, Maurizio Fava, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 5, 2021
Comorbidities and behavioral issuesDragana Bugarski-Kirola, Ronald N Marcus
Schizophrenia Research|August 1, 2013
Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysisJonathan Rabinowitz, Carmen Galani Berardo, Dragana Bugarski-Kirola, et al.
Schizophrenia Bulletin|April 4, 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative SymptomsDragana Bugarski-Kirola, I-Yuan Liu, Celso Arango, et al.
Schizophrenia Bulletin Open|August 15, 2024
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic TreatmentDragana Bugarski-Kirola, Istvan Bitter, I-Yuan Liu, et al.
Frontiers in Psychiatry|September 23, 2022
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophreniaDragana Bugarski-Kirola, Rene Nunez, Ramzey Odetalla, et al.
Patient Preference and Adherence|January 24, 2024
Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE StudiesDragana Bugarski-Kirola, Brandon Abbs, Ramzey Odetalla, et al.
Journal of Clinical Psychopharmacology|October 3, 2022
Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE StudyMona Darwish, Dragana Bugarski-Kirola, Julie Passarell, et al.
Schizophrenia Research|February 10, 2012
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE dataJonathan Rabinowitz, Stephen Z Levine, George Garibaldi, et al.
Journal of Clinical Pharmacology|July 20, 2023
Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of PimavanserinMona Darwish, Dragana Bugarski-Kirola, David Jaworowicz, et al.
The Lancet. Psychiatry|December 3, 2021
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and EuropeDragana Bugarski-Kirola, Celso Arango, Maurizio Fava, et al.
Pageof 2